如此也意味着，在资本市场的喧嚣背后，全球制药行业正以复杂的心态拥抱AI。一方面，AI在提升早 期药物发现效率方面展现出诱人潜力；另一方面，整个AI制药产业仍处于商业化早期，绝大多数公司 尚未实现盈利，其最终价值需通过漫长且高风险的临床试验来验证。不难发现，英矽智能的案例，恰好 为观察这一矛盾中的产业提供了一个绝佳的切片。 战略互补 对于医药产业而言，此次交易受到关注的一大原因在于，英矽智能与施维雅聚焦于"具有挑战性的靶 点"。 一方面，对施维雅而言，这是一次以可控成本获取前沿探索能力的"外包"式创新。传统药企面对难成药 靶点，常因内部研发投入产出比不确定而却步。通过与AI平台合作，施维雅将前期探索的高风险和不 确定性部分转移，以首付款和里程碑付款为杠杆，撬动AI的计算能力，自身则聚焦于擅长的临床开发 与商业化。这是一种风险分散、效率优化的策略，而非根本性的自我颠覆。 另一方面，对英矽智能来说，此次合作的核心价值在于"平台验证"与"现金流补充"。获得跨国药企的背 书，可显著提升其Pharma.AI平台的市场信誉度。高达 3200 万美元的首付款及近期研发里程碑付款，为 公司提供了宝贵的研发资金。这种"服务换现金 ...

中国AI Biotech第一股，来了！ 12月30日，英矽智能正式登陆港股，成为中国首家以生成式人工智能驱动药物研发为核心业务的上市公司，首日高开45%。 这一天，距离英矽智能成立已经过去将近12年的时间，历经行业多轮周期。公司不仅经受住了种种考验，更成长为全球AI制药领域最具代表性的企业之 一。 如今，恰逢生成式AI掀起新一轮技术革命，叠加中国创新药海外BD热潮，作为全球极少数同时具备生成式AI平台、拥有临床阶段管线，并成功达成多笔 高价值对外授权交易的AI Biotech，英矽智能的稀缺价值进一步凸显，值得更多期待。 公司自主研发的核心引擎Pharma.AI平台覆盖从靶点识别、小分子生成、先导化合物优化到临床试验预测的端到端药物研发链条，将候选药物从靶点发现 到临床前候选药物（PCC）确认的时间从传统方法的4.5年缩短至12至18个月。 依托Pharma.AI平台，英矽智能已自主开发出超过20项处于临床或IND申报阶段的创新资产，涵盖纤维化、肿瘤学、免疫学、代谢、抗疼痛等领域，充分 验证了其AI技术在真实药物开发场景中的转化能力。 与此同时，公司已将三项高潜力候选药物授权给国际知名企业，累计最高合约总价值 ...

在全球医药工业向智能化加速转型的进程中，AI制药领域迎来新一轮显著进展。成一项为期多年的研 发合作，协议涉及总金额高达8.88亿美元。双方将聚焦抗肿瘤领域具有挑战性的靶点，共同识别并开发 创新疗法。 根据协议条款，英矽智能(03696)有资格获得最高 3200 万美元的首付款及近期研发里程碑付款，并将依 托其人工智能技术平台，筛选并推进符合既定药物研发和科学标准的潜在候选药物;施维雅则将共同承 担研发成本，并在成功提名具有前景的候选药物后，主导后续的临床验证、监管沟通及相关肿瘤候选药 物在全球范围内的商业化进程。 作为 2026 年生物医药领域 BD的"开年首弹"，这一重磅交易不仅在金额上令人瞩目，更将一个核心议 题推向台前：AI制药是否已跨越漫长的"概念验证"，真正步入规模化"价值实现"的新周期? 包括：与 Exelixis、美纳里尼等公司达成的3项管线授权，总金额最高可达 21亿美元;牵手赛诺菲(总潜在 价值高达 12 亿美元)、礼来(总额逾亿美元)及复星医药（600196）等头部药企，达成AI驱动的药物研发 合作;与诺和诺德、勃林格殷格翰、辉瑞等跨国药企(MNC)达成AI软件对外授权合作。 通过将这种经 ...

Core Insights - The collaboration between Insilico Medicine and Servier, valued at $888 million, marks a significant advancement in the AI-driven pharmaceutical sector, focusing on challenging oncology targets and innovative therapies [1][2] - This partnership highlights the transition of AI in drug development from concept validation to a new cycle of value realization, emphasizing the potential of Insilico's Pharma.AI platform [1][6] Group 1: Partnership Details - The agreement allows Insilico to receive up to $32 million in upfront and milestone payments, leveraging its AI technology to identify and advance drug candidates [1] - Servier will share the R&D costs and lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2: Market Performance - Insilico Medicine's IPO on December 30, 2025, was highly successful, with a subscription rate of approximately 1427 times for the public offering, raising over HKD 328.3 billion [3] - The strong backing from top-tier investors, including Eli Lilly, Tencent, and Temasek, reflects a high consensus on the AI pharmaceutical sector's potential [3] Group 3: Strategic Collaborations - Since 2020, Insilico has established a vast network of global partnerships, achieving multiple AI-driven R&D collaborations and pipeline licenses, with total potential values reaching up to $2.1 billion [4] - Collaborations with major pharmaceutical companies like Sanofi and Eli Lilly further enhance Insilico's capabilities in drug development [4] Group 4: Future Challenges - Despite the promising developments, the true test for AI in drug development will be the clinical trial success rates, as the industry shifts focus from early-stage research to efficacy validation [6] - The upcoming years will be crucial in determining whether AI can effectively disrupt traditional drug development timelines and success rates [6]

Group 1 - The core viewpoint of the article highlights the significant collaboration between Mirxes and Jingtai Technology, aiming to integrate their strengths in early cancer detection and drug development to explore a "diagnosis and treatment integration" solution for high-incidence cancers in Asia [1] - Jingtai Holdings (02228) saw its stock price increase by over 8% in early trading, with a current price of 10.12 HKD and a trading volume of 129 million HKD [1] - Shenwan Hongyuan's research report indicates that Jingtai Holdings has established a complete closed loop for early drug development, leveraging core technologies in "physical computing + AI + robotics" [1] Group 2 - The company's business has expanded from AI drug development to a broader "AI4S" platform, showcasing the potential for its underlying technology to accelerate innovation in drug development and migrate to new materials [1] - The report assigns a "buy" rating for Jingtai Holdings, reflecting confidence in its technological breadth and platform value [1]

Group 1 - InSilico Medicine Cayman TopCo, referred to as "InSilico", officially listed on the Hong Kong Stock Exchange on December 30, with a pre-green shoe financing scale of HKD 22.77 billion and a post-green shoe financing scale of HKD 26.19 billion, assuming full exercise of the green shoe option [2] - This IPO is the largest for an AI pharmaceutical company in Hong Kong and the largest biotech IPO since 2025, reflecting strong market interest and recognition of InSilico's leadership in the AI pharmaceutical sector [2] - The offering attracted 15 cornerstone investors, including Eli Lilly, Tencent, Temasek, Schroders, UBS, Oak Tree Capital, E Fund, and Taikang Life, with international placement oversubscribed by 26.27 times and Hong Kong public offering oversubscribed by approximately 1427.37 times [2] Group 2 - CICC has been supporting InSilico since 2022, providing comprehensive cross-market services and leveraging its expertise in the TMT and pharmaceutical sectors to effectively promote the project and engage with global investors [3] - The project exemplifies CICC's capability in facilitating global capital operations for high-tech enterprises, with plans to continue providing comprehensive financial services to enhance the global competitiveness of international high-tech companies [3] - InSilico is a global AI-driven drug discovery and development company, utilizing its proprietary Pharma.AI platform to generate over 20 clinical or IND-stage assets, with three assets licensed to international pharmaceutical and healthcare companies, totaling a contract value of up to USD 2.1 billion [3]

Core Insights - Hong Kong's IPO market achieved a record fundraising amount of 2856.93 billion HKD in 2025, surpassing Nasdaq and reclaiming the title of the world's largest IPO market, demonstrating the resilience and attractiveness of Hong Kong as an international financial center [4][5][7] Group 1: IPO Market Performance - Six companies, including AI pharmaceutical leader Insilico Medicine, listed simultaneously, raising over 60 billion HKD, contributing to a total of 117 IPOs for the year [3][4] - Insilico Medicine's shares debuted at 24.05 HKD, soaring 45.53% on the first day, while other companies like Lin Qingxuan and Meilian Holdings also showed strong performance [3][4] - The overall IPO first-day performance was mixed, with some companies experiencing significant gains while others, like Woan Robotics and Xunce Technology, had weaker results [3][4] Group 2: Structural Changes in the Market - The surge in IPOs was driven by the unique "A+H" listing model, indicating a shift in the market's function from primarily serving mainland private enterprises to becoming an international distribution center for mature mainland companies [6][8] - A total of 19 A-share companies raised approximately 1399.93 billion HKD in 2025, accounting for half of the total IPO fundraising, highlighting the increasing influence of A-share companies in the Hong Kong market [8] Group 3: Regulatory and Quality Concerns - The rapid growth of the IPO market has raised concerns about the quality of listings, prompting a joint letter from the Hong Kong Stock Exchange and the Securities and Futures Commission addressing issues such as poor drafting quality and inadequate verification of listing documents [9][10] - The overall IPO failure rate decreased to 28.83%, but a rebound in failure rates was observed towards the end of the year, indicating market skepticism towards lower-quality projects [10][11] Group 4: Future Outlook - Despite short-term volatility and quality challenges, forecasts for 2026 remain optimistic, with expectations of around 160 new listings and a fundraising target of at least 3000 billion HKD [12] - Continued inflow of southbound capital, which reached a record net inflow of 1.41 trillion HKD in 2025, is expected to provide substantial liquidity support for the Hong Kong market [12]

Core Viewpoint - The article highlights the successful IPO of six companies on the Hong Kong Stock Exchange on December 30, 2025, showcasing the resilience of the Hong Kong capital market and the diverse sectors represented, including AI pharmaceuticals, digital twins, home robotics, and high-end domestic skincare [1][4]. Group 1: Company Highlights - **卧安机器人 (Woan Robotics)**: Known as the "first AI embodied home robotics stock," it aims to deepen AI technology applications in home life. It holds an 11.9% market share, making it the largest global provider in this sector by retail revenue for 2024 [5]. - **迅策科技 (Xunce Technology)**: The first company in China's AI data sector to complete an IPO on the Hong Kong Stock Exchange. It ranks fourth in the real-time data infrastructure and analytics market and first in the asset management segment, raising 10.8 billion HKD during its IPO [5]. - **英矽智能 (Insilico Medicine)**: The first AI biopharmaceutical company to list under the Hong Kong Stock Exchange's main board rules. It achieved a record oversubscription of approximately 1427.37 times, raising over 328.3 billion HKD in subscription funds [6]. - **五一视界 (51WORLD)**: The first physical AI company to go public in China, it saw a significant opening day increase of 14.75% in its stock price [7]. - **美联股份 (Meilian Holdings)**: The oldest company among the six, focusing on prefabricated steel structure construction, ranking third in the Chinese market with a 3.5% market share [8]. - **林清轩 (Lin Qingxuan)**: Marketed as the "first high-end domestic skincare stock," it focuses on camellia oil research and development, leading the high-end domestic skincare brand market in retail revenue for 2024 [9]. Group 2: Market Insights - The IPO event on December 30, 2025, marked a vibrant conclusion to the Hong Kong IPO market for the year, reflecting a strong recovery with a total of 117 companies listed, raising 285.7 billion HKD [11][15]. - The total funds raised through stock issuance in Hong Kong in 2025 reached approximately 75 billion USD, more than three times that of 2024, indicating a robust return of the Hong Kong capital market [15]. - The ongoing trend shows a surge in AI chip and large model companies seeking to list in Hong Kong, with several companies planning to go public in early 2026 [15].

业务遍布全球的AI驱动生物科技公司。 据IPO早知道消息，InSilico Medicine Cayman TopCo（以下简称"英矽智能"）于2025年12月30日正式以"3696"为股票代码在港交所主板挂牌上市。 这意味着，英矽智能成为首家通过联交所主板上市规则8.05条上市的人工智能生物医药科技公司。 值得一提的是，英矽智能本次IPO募集资金总额为22.77亿港元，是年内募集资金最高的港股生物医药IPO。同时，英矽智能本次香港发售获1427.37倍超额 认购，锁定认购资金逾3283.49亿港元，创下年内非18A港股医疗健康IPO香港公开发售认购金额之最；国际发售占比90%，录得26.27倍超额认购，创下年内 非18A港股医疗健康IPO国际配售认购倍数之最。 此外，英矽智能在本次IPO发行中还引入包括礼来公司、腾讯、淡马锡、施罗德、瑞银、橡树资本、易方达、泰康人寿等在内的15家全球化基石投资者，阵 容涵盖全球制药龙头、互联网巨头、国际主权基金与大型资管机构以及国内头部公募与险资。 截至11:00，英矽智能报于每股34.16港元，较发行价上涨42.04%，市值超190亿港元。 英矽智能创始人兼首席执行官、首 ...

经济观察报记者张铃 此次英矽智能引入包括礼来、腾讯、淡马锡、施罗德、瑞银、橡树资本、易方达、泰康人寿等在内的15 家基石投资者，涵盖全球制药龙头、互联网巨头、国际主权基金与大型资管机构以及国内头部公募与险 资。这也是礼来与腾讯首次认购生物医药企业基石投资。 值得注意的是，英矽智能是第一家通过联交所主板上市规则8.05条上市的AI制药公司，该规则要求企业 既要有未来的管线预期，也要通过严格的盈利或收入测试，具备商业化落地的实证。 英矽智能的核心资产为一款治疗特发性肺纤维化的药物Rentosertib，这是业界进展最领先的全球首创 (first-in-class)AI药物，目前已在国内完成IIa期临床研究，标志着AI驱动药物开发的重要里程碑。 迄今，英矽智能已与全球前20大制药公司中的13家达成软件授权合作。另外，英矽智能已与Exelixis、 美纳里尼等全球制药企业达成了3项管线对外授权合作，合作总额最高可达21亿美元，并与复星医药 （600196）(600196.SH，02196.HK)、赛诺菲、礼来等全球知名制药企业达成了共同研发合作。 2025年12月30日，明星AI制药公司英矽智能(03696.HK)在 ...